United Therapeutics Corporation (UTHR)

UTHR Financials

UTHR Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Revenue	3.170B	781.500M	790.200M	799.500M	798.600M	794.400M	735.900M	748.900M	714.900M
Cost of Goods Sold	425.300M	133.400M	103.400M	100.900M	87.600M	92.500M	75.900M	83.100M	77.800M
Gross Profit	2.744B	648.100M	686.800M	698.600M	711.000M	701.900M	660.000M	665.800M	637.100M
Gross Profit Margin	82.9%	82.9%	86.9%	87.4%	89.0%	88.4%	89.7%	88.9%	89.1%
Total Operating Expenses	1.307B	322.300M	329.300M	309.300M	346.500M	319.100M	302.300M	322.700M	317.200M
Research & Development	539.200M	138.200M	139.500M	127.500M	134.000M	149.000M	133.800M	103.500M	139.600M
Selling, General & Administrative	746.500M	184.100M	189.800M	181.800M	190.800M	170.100M	162.500M	219.200M	177.600M
Operating Income (EBIT)	1.437B	325.800M	357.500M	389.300M	364.500M	382.800M	357.700M	343.100M	319.900M
Operating Margin	41.7%	41.7%	45.2%	48.7%	45.6%	48.2%	48.6%	45.8%	44.7%
Income Before Tax (EBT)	1.609B	318.300M	444.000M	438.000M	408.400M	423.500M	396.500M	388.600M	355.300M
Interest Income	182.700M	41.800M	43.200M	46.400M	51.300M	51.100M	49.300M	49.800M	46.200M
Interest Expense	16.400M	3.000M	3.100M	3.000M	7.300M	6.100M	7.900M	10.100M	11.600M
Other Income/Expense	171.600M	-7.500M	86.500M	48.700M	43.900M	40.700M	38.800M	45.500M	35.400M
Net Income	1.287B	274.900M	364.300M	338.700M	309.500M	322.200M	301.300M	309.100M	278.100M
Income Tax Expense	321.300M	43.400M	79.700M	99.300M	98.900M	101.300M	95.200M	79.500M	77.200M
Net Profit Margin	35.2%	35.2%	46.1%	42.4%	38.8%	40.6%	40.9%	41.3%	38.9%
EBITDA	1.714B	343.900M	469.900M	462.900M	436.800M	382.800M	424.100M	417.800M	385.600M
EBITDA Margin	44.0%	44.0%	59.5%	57.9%	54.7%	48.2%	57.6%	55.8%	53.9%
Depreciation & Amortization	88.400M	22.600M	22.800M	21.900M	21.100M	-34.600M	19.700M	19.100M	18.700M
EPS Basic	29.27	6.32	8.36	7.73	6.86	7.18	6.74	6.93	6.26
EPS Diluted	27.05	5.82	7.66	7.16	6.41	6.63	6.19	6.39	5.85
Shares Outstanding	43.500M	43.500M	44.300M	43.800M	45.100M	44.900M	45.200M	44.600M	44.400M
Diluted Shares Outstanding	47.200M	47.200M	47.900M	47.300M	48.300M	48.600M	48.700M	48.400M	47.500M

UTHR Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.183B	2.877B	2.328B	1.936B	1.685B	1.483B	1.449B	1.628B
Cost of Goods Sold	384.400M	309.700M	257.500M	146.700M	122.500M	108.100M	117.600M	198.700M
Gross Profit	2.798B	2.568B	2.070B	1.790B	1.563B	1.375B	1.331B	1.429B
Gross Profit Margin	87.9%	89.2%	88.9%	92.4%	92.7%	92.7%	91.9%	87.8%
Total Operating Expenses	1.281B	1.191B	885.100M	809.900M	1.007B	781.600M	1.519B	623.700M
Research & Development	550.000M	481.000M	408.000M	322.900M	540.100M	357.700M	1.183B	357.900M
Selling, General & Administrative	731.100M	638.600M	477.100M	487.000M	467.000M	423.900M	336.200M	265.800M
Operating Income (EBIT)	1.517B	1.377B	1.185B	979.700M	555.900M	593.600M	-187.600M	805.400M
Operating Margin	47.7%	47.9%	50.9%	50.6%	33.0%	40.0%	-12.9%	49.5%
Income Before Tax (EBT)	1.714B	1.539B	1.274B	950.600M	593.900M	638.900M	-165.000M	758.900M
Interest Income	192.000M	199.100M	162.700M	45.200M	16.700M	28.600M	44.200M	28.600M
Interest Expense	19.500M	42.900M	59.300M	32.400M	18.600M	23.500M	44.200M	13.900M
Other Income/Expense	196.700M	162.000M	89.400M	-29.100M	38.000M	45.300M	22.600M	-46.500M
Net Income	1.335B	1.195B	984.800M	727.300M	475.800M	514.800M	-104.500M	589.200M
Income Tax Expense	379.200M	343.900M	289.500M	223.300M	118.100M	124.100M	-60.500M	169.700M
Net Profit Margin	41.9%	41.5%	42.3%	37.6%	28.2%	34.7%	-7.2%	36.2%
EBITDA	1.819B	1.654B	1.387B	1.040B	736.800M	646.300M	-74.900M	838.400M
EBITDA Margin	57.2%	57.5%	59.6%	53.7%	43.7%	43.6%	-5.2%	51.5%
Depreciation & Amortization	85.600M	72.500M	53.200M	51.300M	49.900M	49.900M	45.900M	35.900M
EPS Basic	30.13	26.44	21.04	15.98	10.60	11.65	-2.39	13.54
EPS Diluted	27.86	24.64	19.81	15.00	10.06	11.54	-2.39	13.39
Shares Outstanding	44.300M	45.200M	46.800M	45.500M	44.900M	44.200M	43.800M	43.500M
Diluted Shares Outstanding	47.900M	48.500M	49.700M	48.500M	47.300M	44.600M	43.800M	44.000M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,305 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials